Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer’s Disease: Present Status and Future Opportunities
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by cognitive inability manifested due to the accumulation of β-amyloid, formation of hyper phosphorylated neurofibrillary tangles, and a malfunctioned cholinergic system. The degeneration integrity of the neuronal network can appear long after the onset of the disease. Nanotechnology-based interventions have opened an exciting area via theranostics of AD in terms of tailored nanomedicine, which are able to target and deliver drugs across the blood-brain barrier (BBB). The exciting interface existing between medicinal plants and nanotechnology is an emerging marvel in medicine, which has delivered promising results in the treatment of AD. In order to assess the potential applications of the medicinal plants, their derived components, and various nanomedicinal approaches, a review of literature was deemed as necessary. In the present review, numerous phytochemicals and various feats in nanomedicine for the treatment of AD have been discussed mechanistically for the first time. Furthermore, recent trends in nanotechnology such as green synthesis of metal nanoparticles with reference to the treatment of AD have been elaborated. Foreseeing the recent progress, we hope that the interface of medicinal plants and nanotechnology will lead to highly effective theranostic strategies for the treatment of AD in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499 · cited 1×
“…clinical symptoms of AD patients include impairment in memory, e.g., current conversations, names or events, while later symptoms comprises poor communication, misperception, confusion, misjudgment, changed attitude, and finally, difficulty in speaking, swallowing, and walking (Khachaturian, 1985).”
BackgroundYang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
Lim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. A., & Cole, G. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08370.2001 · Cited by 1,530
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Aggarwal, B. B., & Sung, B. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.11.002 · Cited by 1,140 · cited 1×
“Several other studies signify the potential use of curcumin in the management of neurodegenerative disorders like AD and its possible mechanism of action (Baum and Ng, 2004; Aggarwal and Sung, 2009).”
BackgroundNeutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin
Zenaro, E., Pietronigro, E., Bianca, V. D., Piacentino, G., Marongiu, L., Budui, S., Turano, E., Rossi, B., Angiari, S., Dusi, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3913 · Cited by 865
Functional Properties of Coffee and Coffee By-Products
Esquivel, P., & Jiménez, V. M. (2012) · Food Research International · doi:10.1016/j.foodres.2011.05.028 · Cited by 847 · cited 2×
“Caffeine and 5-caffeoylquinic acid (chlorogenic acid)enriched coffee extensively crosses BBB and exhibits numerous CNS effects including neurotropic, anti-AD, and neuroprotective properties (Ito et al., 2008; Chu et al., 2009; Kwon et al., 2010; Cropley et al., 2012; Esquivel and Jiménez, 2012; Oboh et al., 2013).”
BackgroundNanoparticles for direct nose-to-brain delivery of drugs
Mistry, A., Stolnik, S., & Illum, L. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.06.019 · Cited by 734
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677
Begum, A. N., Jones, M. R., Lim, G. P., Morihara, T., Kim, P., Heath, D. D., Rock, C. L., Pruitt, M. A., Yang, F., Hudspeth, B., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137455 · Cited by 604
Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier
Lockman, P. R., Mumper, R. J., Khan, M. A., & Allen, D. D. (2002) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120001481 · Cited by 592
Ulbrich, K., Hekmatara, T., Herbert, E., & Kreuter, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.021 · Cited by 591
Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
Tiwari, S. K., Agarwal, S., Seth, B., Yadav, A., Nair, S., Bhatnagar, P., Karmakar, M., Kumari, M., Chauhan, L. K. S., Patel, D. K., et al. (2014) · ACS Nano · doi:10.1021/nn405077y · Cited by 558
Baum, L., & Ng, A. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6403 · Cited by 483
Pardeshi, C. V., & Belgamwar, V. S. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.790887 · Cited by 482
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448
Kwon, S.-H., Lee, H.-K., Kim, J.-A., Hong, S.-I., Kim, H.-C., Jo, T.-H., Park, Y.-I., Lee, C.-K., Kim, Y.-B., Lee, S.-Y., et al. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.001 · Cited by 437
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370
Wilson, B., Samanta, M. K., Santhi, K., Kumar, K. P. S., Paramakrishnan, N., & Suresh, B. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.039 · Cited by 363
Genetic aspects of Alzheimer disease.
Bird, T. D. (2008) · Genetics in Medicine · doi:10.1097/gim.0b013e31816b64dc · Cited by 356
Oboh, G., Agunloye, O. M., Akinyemi, A. J., Ademiluyi, A. O., & Adefegha, S. A. (2013) · Neurochemical Research · doi:10.1007/s11064-012-0935-6 · Cited by 333 · cited 1×
“…acid (chlorogenic acid)enriched coffee extensively crosses BBB and exhibits numerous CNS effects including neurotropic, anti-AD, and neuroprotective properties (Ito et al., 2008; Chu et al., 2009; Kwon et al., 2010; Cropley et al., 2012; Esquivel and Jiménez, 2012; Oboh et al., 2013).”
BackgroundNeuropharmacological Review of the Nootropic Herb Bacopa monnieri
Aguiar, S., & Borowski, T. (2013) · Rejuvenation Research · doi:10.1089/rej.2013.1431 · Cited by 295
Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats
Ishisaka, A., Ichikawa, S., Sakakibara, H., Piskula, M. K., Nakamura, T., Kato, Y., Ito, M., Miyamoto, K.-I., Tsuji, A., Kawai, Y., et al. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.017 · Cited by 293
Neuroprotective Actions of Dietary Choline
Blusztajn, J., Slack, B., & Mellott, T. (2017) · Nutrients · doi:10.3390/nu9080815 · Cited by 293
Preclinical Alzheimer disease—the challenges ahead
Sperling, R. A., Karlawish, J., & Johnson, K. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.241 · Cited by 291
Smith, A., Giunta, B., Bickford, P. C., Fountain, M., Tan, J., & Shytle, R. D. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.01.012 · Cited by 280
Akhondzadeh, S., Shafiee Sabet, M., Harirchian, M. H., Togha, M., Cheraghmakani, H., Razeghi, S., Hejazi, S. S., Yousefi, M. H., Alimardani, R., Jamshidi, A., et al. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1706-1 · Cited by 268
Anti-cancer green bionanomaterials: present status and future prospects
Barabadi, H., Ovais, M., Shinwari, Z. K., & Saravanan, M. (2017) · Green Chemistry Letters and Reviews · doi:10.1080/17518253.2017.1385856 · Cited by 221
Self-citationAnti-Alzheimer’s Studies on β-Sitosterol Isolated from Polygonum hydropiper L.
Ayaz, M., Junaid, M., Ullah, F., Subhan, F., Sadiq, A., Ali, G., Ovais, M., Shahid, M., Ahmad, A., Wadood, A., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00697 · Cited by 220
Self-citationNeurotherapeutic applications of nanoparticles in Alzheimer’s disease
Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219
Dhanasekaran, M., Holcomb, L. A., Hitt, A. R., Tharakan, B., Porter, J. W., Young, K. A., & Manyam, B. V. (2009) · Phytotherapy Research · doi:10.1002/ptr.2405 · Cited by 175
Neurocognitive Effect of Nootropic Drug Brahmi (Bacopa monnieri) in Alzheimer's Disease
Chaudhari, K. S., Tiwari, N. R., Tiwari, R. R., & Sharma, R. S. (2017) · Annals of Neurosciences · doi:10.1159/000475900 · Cited by 167
Balducci, C., Mancini, S., Minniti, S., La Vitola, P., Zotti, M., Sancini, G., Mauri, M., Cagnotto, A., Colombo, L., Fiordaliso, F., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0284-14.2014 · Cited by 162
Krishnamurthy, R. G., Senut, M., Zemke, D., Min, J., Frenkel, M. B., Greenberg, E. J., Yu, S., Ahn, N., Goudreau, J., Kassab, M., et al. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22071 · Cited by 155
Liu, G., Men, P., Kudo, W., Perry, G., & Smith, M. A. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.03.064 · Cited by 148
Md, S., Ali, M., Baboota, S., Sahni, J. K., Bhatnagar, A., & Ali, J. (2014) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.758130 · Cited by 138
Exploring the Role of “Brahmi” (Bacopa monnieri and Centella asiatica) in Brain Function and Therapy
G.K., S., Muralidhara, & M.S. Bharath, M. (2011) · Recent Patents on Endocrine, Metabolic & Immune Drug Discovery · doi:10.2174/187221411794351833 · Cited by 131
Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line.
Markoutsa, E., Pampalakis, G., Niarakis, A., Romero, I. A., Weksler, B., Couraud, P.-O., & Antimisiaris, S. G. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.11.015 · Cited by 122
Alzheimer's drug‐development pipeline: 2016
Cummings, J., Morstorf, T., & Lee, G. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.07.001 · Cited by 108
Chu, Y.-F., Brown, P. H., Lyle, B. J., Chen, Y., Black, R. M., Williams, C. E., Lin, Y.-C., Hsu, C.-W., & Cheng, I. H. (2009) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf902095z · Cited by 89
Nootropic activity of Celastrus paniculatus seed
Bhanumathy, M., Harish, M. S., Shivaprasad, H. N., & Sushma, G. (2010) · Pharmaceutical Biology · doi:10.3109/13880200903127391 · Cited by 88
Godkar, P. B., Gordon, R. K., Ravindran, A., & Doctor, B. P. (2006) · Phytomedicine · doi:10.1016/j.phymed.2003.11.011 · Cited by 72
Treatment of Alzheimers Disease: Symptomatic and Disease-Modifying Approaches
Galimberti, D., & Scarpini, E. (2010) · Current Aging Science · doi:10.2174/1874609811003010046 · Cited by 51
Chen, Z., Mao, X., Liu, A., Gao, X., Chen, X., Ye, M., Ye, J., Liu, P., Xu, S., Liu, J., et al. (2015) · Neurochemical Research · doi:10.1007/s11064-014-1483-z · Cited by 51
Geiser, R. J., Chastain, S. E., & Moss, M. A. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2016.11.1965 · Cited by 11
Cited by
Biosynthesis of Metal Nanoparticles via Microbial Enzymes: A Mechanistic Approach
Ovais, M., Khalil, A. T., Ayaz, M., Ahmad, I., Nethi, S. K., & Mukherjee, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124100 · Cited by 475
Self-citationAyaz, M., Ullah, F., Sadiq, A., Ullah, F., Ovais, M., Ahmed, J., & Devkota, H. P. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.05.050 · Cited by 359
Self-citationPatil, S., & Chandrasekaran, R. (2020) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-020-00081-3 · Cited by 347
Ayaz, M., Sadiq, A., Junaid, M., Ullah, F., Ovais, M., Ullah, I., Ahmed, J., & Shahid, M. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00155 · Cited by 320
Self-citationApplications of Phyto-Nanotechnology for the Treatment of Neurodegenerative Disorders
Bhattacharya, T., Soares, G. A. B. E., Chopra, H., Rahman, M. M., Hasan, Z., Swain, S. S., & Cavalu, S. (2022) · Materials · doi:10.3390/ma15030804 · Cited by 259
Metadata
- Authors
- Ovais, M., Zia, N., Ahmad, I., Khalil, A. T., Raza, A., Ayaz, M., Sadiq, A., Ullah, F., & Shinwari, Z. K.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-10-23
- Volume
- 10
- Pages
- 284-284
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2896526587
- Cited by
- 138
- References
- 55
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.